Single Dose Thymoglobulin for Induction in Adult Renal Allograft Recipients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The aim of this trial is to compare the safety and efficacy of a single dose of Thymoglobulin, rabbit derived antithymocyte globulin (Thymoglobulin, SangStat, Fremont, CA) to our standard four dose, four day Thymoglobulin induction regimen from the time of transplantation through a six month follow-up period. The primary endpoint will be the incidence of acute rejection. Secondary endpoints will include serious adverse events, evaluation of renal function, patient and graft survival, incidence of infectious complications, incidence of post-transplantation lymphoproliferative disorder (PTLD), duration and extent of lymphocyte depletion and immunoassays for evidence of recipient immune response to the allograft as well as duration of hospital stay.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients 18 years of age or older
All consenting adult renal transplant recipients scheduled to receive induction therapy (deceased donor, living-related, or living-unrelated)
Females of childbearing age must have a negative pregnancy test performed at the time of admission for transplantation
Patient or guardian agrees to participate in the study and signs the informed consent.
No known contraindication to the administration of Thymoglobulin
A known allergy to rabbit proteins or previous significant intolerance of Thymoglobulin administration
Pregnant women or nursing mothers
Patients with serological evidence of infection with HIV-1, human T-cell leukemia virus type 1 (HTLV-1), or the presence of serum hepatitis B surface antigen (HBsAg)
Recipients of a human leukocyte antigen (HLA) identical living donor renal allograft (2-haplotype match)
Recipients of simultaneous multiple organ transplantation
Recipients with a pre-existing, non-renal, solid organ transplant
Recipients of ≥2 previous renal allografts
Patients with a history of malignancy with evidence of recurrence within 2 years (except adequately treated localized squamous or basal cell carcinoma of the skin).
Any patient who, in the opinion of the investigator, has a significant medical or psychosocial problem that should preclude them from the study.